Nanz Med Science Pharma Private Limited - Company Profile

It is a pharma private limited company based in New Delhi, Delhi, India, established in 2006.
2006 New Delhi, Delhi, India Active
Last Updated:
About Nanz Med Science Pharma Private Limited

Nanz Med Science Pharma Private Limited, a active private limited company, was established on 19 December 2006 in New Delhi, Delhi, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U24100DL2006PTC156756. Registered under ROC Roc Delhi. it is unlisted. It has an authorized capital of ₹15.00 Cr and a paid-up capital of ₹12.11 Cr.

It upholds a compliant status. Employing 450 professional, Its leadership includes Manmit Singh Malhotra (Managing Director), Harpreet Singh Puri (Additional Director), Sunpreet Kaur Puri (Additional Director). Past directors included Manmit Singh Malhotra, Rakesh Bajaj, Inderjit Malik. It holds ₹105.15 Cr open charges and ₹46.50 Cr settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at C-168 Ground Floor, Naraina Industrial Area, Phase I, New Delhi, Delhi, 110028.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    U24100DL2006PTC156756

  • Registration Number

    156756

  • Incorporation Date

    19 December 2006

  • Authorized Capital

    ₹15.00 Cr

  • Paid-Up Capital

    ₹12.11 Cr

  • ROC Code

    Roc Delhi

  • Listing Status

    Unlisted

  • Company Status

    Active

Key Metrics
  • Authorised Capital ₹ 15.00 Cr
  • Paid Up Capital ₹ 12.11 Cr
  • Company Age 19 Year, 2 Months
  • Last Filing with ROC 31 Mar 2024
  • Open Charges ₹ 105.15 Cr
  • Satisfied Charges ₹ 46.50 Cr
  • Revenue Growth **** 22.49%
  • Profit Growth **** 138.80%
  • Ebitda **** 71.75%
  • Net Worth 16.25%
  • Total Assets **** 9.72%
Company report

Nanz Med Science Pharma Private Limited

Company Report FY 2025-2026

Comprehensive Company Insights

Explore comprehensive insights into Nanz Med Science Pharma Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report
Who are the key members and board of directors at Nanz Med Science Pharma Private Limited?
Current Directors
Name Designation Appointment Date Status
Manmit Singh Malhotra Managing Director 01 Apr 2009 Current
Harpreet Singh Puri Additional Director 15 Nov 2024 Current
Sunpreet Kaur Puri Additional Director 15 Nov 2024 Current
Lakhvinder Pal Singh Director 01 Oct 2007 Current
Past Directors
Name Designation Cessation Status
Pramod Abcsdd Director 16 Aug 2024 Past
Pramod Abcsdd Additional Director 21 Jan 2022 Past
Pramod Abcsdd Director 19 Nov 2018 Past
Pramod Abcsdd Company Secretary - Past
Pramod Abcsdd Director 09 Feb 2008 Past
Pramod Abcsdd Director 01 Oct 2007 Past

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Nanz Med Science Pharma.

Nanz Med Science Pharma Private Limited, for the financial year ended 2024, experienced significant growth in revenue, with a 22.49% increase. The company also saw a substantial improvement in profitability, with a 138.8% increase in profit. The company's net worth Soared by an impressive increase of 16.25%.

Nanz Med Science Pharma revenue growth over time
Nanz Med Science Pharma profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
22.49%
*******
*******
*******
*******
Revenue from Operations
*******
21.75%
*******
*******
*******
*******
Total Assets
*******
9.72%
*******
*******
*******
*******
Profit or Loss
*******
138.80%
*******
*******
*******
*******
Net Worth
*******
16.25%
*******
*******
*******
*******
EBITDA
*******
71.75%
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Nanz Med Science Pharma?

In 2024, Nanz Med Science Pharma had a promoter holding of 86.50% and a public holding of 13.50%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

Charges (Loans)
Open Charges

₹1,051,457,423.00

Satisfied Charges

₹465,043,093.00

Charges Breakdown by Lending Institutions
  • Hdfc Bank Limited : 91.48 Cr
  • Tata Capital Financial Services Limited : 7.67 Cr
  • Others : 6.00 Cr
Latest Charge Details
Date Lender Amount Status
10 Nov 2025 Hdfc Bank Limited ₹0.85 M Open
23 Dec 2024 Others ₹6.00 Cr Open
15 Jan 2024 Hdfc Bank Limited ₹2.81 M Open
18 Dec 2023 Tata Capital Financial Services Limited ₹3.00 Cr Open
15 Nov 2023 Hdfc Bank Limited ₹4.40 M Open

Explore comprehensive loan charge details -

How Many Employees Work at Nanz Med Science Pharma?

Nanz Med Science Pharma has a workforce of 450 employees as of Mar 05, 2025. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Nanz Med Science Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nanz Med Science Pharma's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Nanz Med Science Pharma
Recent Activity within the Organization
  • Charges

    Progress on A charge with Hdfc Bank Limited amounted to Rs. 0.09 Cr with Charge ID 101184304 was registered on 10 Nov 2025. was documented.

  • Charges

    Progress on A charge with Hdfc Bank Limited of Rs. 90.05 Cr registered on 04 Feb 2016 with Charge ID 10620352 was modified on 31 Jul 2025. was documented.

  • Charges

    A charge with Others amounted to Rs. 6.00 Cr with Charge ID 101041345 was registered on 23 Dec 2024. was recorded as a recent event.

  • Director Appointment

    Progress on Harpreet Singh Puri was appointed as a Additional Director was appointed as a Additional Director on 15 Nov 2024 & has been associated with this company since 1 year 3 months . was documented.

  • Director Appointment

    Sunpreet Kaur Puri was appointed as a Additional Director was appointed as a Additional Director on 15 Nov 2024 & has been associated with this company since 1 year 3 months . was recorded as a recent event.

  • Annual General Meeting

    Nanz Med Science Pharma Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was recorded as a recent event.

Explore recent activity and updates - View Recent Activity

Frequently Asked Questions
What is the CIN of Nanz Med Science Pharma Private Limited?

The CIN of Nanz Med Science Pharma Private Limited is U24100DL2006PTC156756.

Where is Nanz Med Science Pharma Private Limited headquartered?

Nanz Med Science Pharma Private Limited is headquartered at C-168 Ground Floor, Naraina Industrial Area, Phase I, New Delhi, Delhi, 110028.

When was Nanz Med Science Pharma Private Limited incorporated?

Nanz Med Science Pharma Private Limited was incorporated on 19 December 2006.

Who are the current directors of Nanz Med Science Pharma Private Limited?

The current directors of Nanz Med Science Pharma Private Limited are

What is the primary industry of Nanz Med Science Pharma Private Limited?

The primary industry of Nanz Med Science Pharma Private Limited is Manufacturing.

Is Nanz Med Science Pharma Private Limited a listed company?

Nanz Med Science Pharma Private Limited is unlisted.

What is the capital structure of Nanz Med Science Pharma Private Limited?

The authorized capital of Nanz Med Science Pharma Private Limited is ₹15.00 Cr, and the paid-up capital is ₹12.11 Cr.

What is the compliance status of Nanz Med Science Pharma Private Limited?

The compliance status of Nanz Med Science Pharma Private Limited is Compliant.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available